AQST Aquestive Therapeutics, Inc.
$4.07▲ +2.52%
Healthcare
Other
After hours
$4.07▲ +0.00%
Oct 27, 4:01 PM ET
Volume 1.32M
Avg Volume (10D) 2.58M
Key Metrics & Fundamentals
Market Cap
$510.83M
P/E Ratio
–
Div Yield
0.00%
52W Range
2.93 - 7.05
% vs 50 MA
-13.11%
% vs 200 MA
-3.09%
RSI-14
40.3
MACD Histogram
-0.0300
Beta (1Y vs SPY)
0.81
Free Cash Flow
-$9.65M
Gross Rev
$13.82M
Gross Profit
$9.80M
EBITDA
-$7.21M
COGS
$4.02M
Operating Exp
$18.03M
Operating Income
-$8.22M
EBIT
-$8.22M
Pretax Income
-$22.86M
Net Income
-$22.86M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
GlobeNewswire · Oct 27, 2026 7:00 AM ET
Aquestive Therapeutics Says FDA Accepts Resubmitted Filing for Anaphylm in Severe Allergy
MT Newswires · Oct 15, 2026 7:32 AM ET
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
GlobeNewswire · Oct 15, 2026 7:00 AM ET
Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday
MT Newswires · Oct 14, 2026 9:23 AM ET
Eton Pharmaceuticals Licenses US Rights to Aquestive's Epilepsy Drug
MT Newswires · Oct 14, 2026 7:15 AM ET
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
GlobeNewswire · Oct 14, 2026 6:50 AM ET
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
GlobeNewswire · Sep 29, 2026 7:00 AM ET
Aquestive Therapeutics Resubmits Anaphylm NDA to FDA
MT Newswires · Sep 17, 2026 7:26 AM ET
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
GlobeNewswire · Sep 17, 2026 7:00 AM ET
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
Insider Monkey · Sep 7, 2026 10:07 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See AQST's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.